JW Pharmaceutical Buys Group's Venture Arm Solidus for 30.7 Billion Won

JW Pharmaceutical will pay 30.7 billion won ($22 million) for a 100% stake in Solidus Investment, moving the group's corporate venture capital arm from holding company JW Holdings to the group's main operating company.

The company disclosed the deal in a regulatory filing on September 29, 2026, according to a report by Han Tae-hee in the Seoul Economic Daily. JW Pharmaceutical said the acquisition is intended to accelerate open innovation and secure new growth drivers.

What does the deal change inside the group?

The transaction reshuffles JW Group's governance structure. Solidus Investment, previously a subsidiary of JW Holdings (096760), becomes a direct subsidiary of JW Pharmaceutical (001060), the group's main operating company.

The move follows JW Holdings' removal from holding company status under the Fair Trade Act in June. Under Korean law, a general holding company cannot hold a corporate venture capital firm as a second-tier subsidiary; it must own such a firm as a wholly owned direct subsidiary. The Seoul Economic Daily reports that JW Holdings is understood to have been freed from those restrictions once it lost its holding company classification.

How did the group's ownership of Solidus evolve?

The timeline of the unit's ownership has shifted twice within a single year:

• March 2026: JW Holdings acquired Solidus Investment for 30.6 billion won and brought it in as a subsidiary.
• June 2026: JW Holdings was removed from holding company status under the Fair Trade Act.
• September 29, 2026: JW Pharmaceutical announced the 30.7 billion won buyout of the entire stake from JW Holdings.

The price marks a marginal 100 million won step-up from the holding company's purchase price seven months earlier.

What is the strategic rationale?

A JW Pharmaceutical group official framed the deal as a way to tie the VC unit's biotech investment expertise directly to the drugmaker's research engine. The official called the acquisition "a strategic decision to link Solidus' specialized investment capabilities in the biotech field more closely with our research and development and business development capabilities."

The group also signaled a medium-term ambition for the unit. "We will expand open innovation opportunities to complement our in-house research and development capabilities and, over the medium to long term, broaden our new drug pipeline and new growth opportunities," the official said.

In practice, the restructuring gives the operating company direct control over strategic investments, positioning Solidus as a tool for external deal sourcing rather than a passive financial holding at the group level.

Why does the holding company law matter here?

The Fair Trade Act constraint drove the group's options. As long as JW Holdings held holding company status, the law dictated where a corporate venture capital firm could sit in its ownership tree. Losing that status in June removed the legal restriction, and the group then chose to park Solidus with the pharma operating company — the unit best positioned to use the VC arm's biotech deal flow — rather than keep it at the holding level.

The structure now aligns the investment arm with the part of the group that runs research and development and business development, the functions JW Pharmaceutical says it wants to complement through open innovation.

For JW Pharmaceutical, the immediate financial outlay is modest at 30.7 billion won, but the deal hands the operating company a dedicated biotech investment vehicle. The company says it expects the unit to widen its new drug pipeline and generate new growth opportunities over the medium to long term.